Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Implements 30% workforce reduction, focusing on three clinical-stage immunotherapy programs.
  • Cash runway extended through Q3 2027 with CHF 127.1 million in resources.
  • Interim clinical data from ACI-7104.056 expected H2 2025, ACI-24.060 in H1 2026.

AC Immune SA (NASDAQ: ACIU) has announced a strategic restructuring aimed at streamlining operations and concentrating resources on its highest-value programs. The plan includes a 30% workforce reduction and a narrowed focus on three clinical-stage active immunotherapy programs, along with small molecule programs targeting NLRP3 and Tau proteins.

According to the company, this restructuring will extend its cash runway through Q3 2027, supported by cash and equivalents totaling CHF 127.1 million as of June 30, 2025. Cost reductions are expected to be fully effective in early 2026 following the completion of the restructuring by year-end 2025.

AC Immune emphasized that clinical development timelines remain on track despite the workforce reduction. Interim data from its ACI-7104.056 program is anticipated in the second half of 2025, while ACI-24.060 data is expected in the first half of 2026. The company’s partnerships with Janssen, Takeda, and Lilly remain intact, which may support ongoing research and development efforts.

The restructuring is designed to focus resources on late-stage and high-value candidates, potentially improving efficiency in advancing therapies toward commercialization. However, the narrowing of pipeline priorities may limit the company’s ability to pursue earlier-stage exploratory programs.

In the near term, AC Immune expects to incur restructuring-related expenses, including severance and transition support for affected employees. While these costs will impact short-term financial results, the longer-term outcome is expected to be improved capital allocation and operational efficiency.